Pilot Trial of Transnasal Nicotine in Parkinson Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 4, 2019

Primary Completion Date

November 2, 2019

Study Completion Date

November 2, 2019

Conditions
Parkinson Disease
Interventions
DRUG

Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)

Patients will receive incremental doses of Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) starting with 3 bilateral puffs per day (3 mg total) for 3 days, followed by 5 bilateral puffs per day (5 mg) for 3 days, followed by 8 bilateral puffs per day (8 mg) for 4 days, followed by 10 bilateral puffs per day (10 mg) for 10 days.

Trial Locations (1)

14269

Instituto Nacional de Neurología y Neurocirugía MVS, Mexico City

All Listed Sponsors
collaborator

Howard University

OTHER

lead

El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez

OTHER

NCT03865121 - Pilot Trial of Transnasal Nicotine in Parkinson Disease | Biotech Hunter | Biotech Hunter